Evidence review
Lutein and zeaxanthin for eye health: evidence reviewed
The key evidence comes from AREDS2, a National Eye Institute trial of 4,203 people at risk of advanced age-related macular degeneration. Adding lutein 10 mg and zeaxanthin 2 mg to the existing AREDS formula did not significantly reduce progression in the primary analysis, though secondary analyses suggested benefit, especially for people with low dietary intake and when lutein replaced beta-carotene. The trial did not show a reduction in cataract surgery or benefit for people with healthy eyes.
Ingredient evidence ≠ product proof
This page reviews research on an ingredient. It does not show that any branded supplement containing that ingredient works, because commercial products may use a different form, dose or combination, and are rarely tested themselves. This is an evidence page: it contains no affiliate links.
The research question
Do lutein and zeaxanthin supplements slow progression of age-related macular degeneration, or reduce cataract, in older adults?
Evidence table: population → dose → duration → result → limitations
| Study | Population | Dose / intervention | Duration | Result | Limitations |
|---|---|---|---|---|---|
| AREDS2, JAMA 2013 | 4,203 adults aged 50–85 at risk of advanced AMD | AREDS formula ± lutein 10 mg/zeaxanthin 2 mg, ± omega-3; beta-carotene and zinc variations | Median about 5 years | No significant additional reduction in progression to advanced AMD (primary analysis) | Tested on top of an already effective formula |
| AREDS2 report 3, 2014 | Same cohort | Secondary analyses | As above | Benefit suggested in lowest dietary-intake group; lutein/zeaxanthin better than beta-carotene in direct comparison | Secondary analyses; hypothesis-generating |
| AREDS2 report 4, 2013 | Participants with natural lenses | Lutein 10 mg/zeaxanthin 2 mg vs none | As above | No overall reduction in progression to cataract surgery | Population at risk of AMD |
What the results show
AREDS2 was large, long and publicly funded, which makes it the most important evidence here. Its primary result for adding lutein and zeaxanthin was not statistically significant. The recommended formula still changed: lutein and zeaxanthin replaced beta-carotene, which had been linked to lung cancer risk in smokers and former smokers. The National Eye Institute AREDS/AREDS2 FAQ also notes that lowering zinc did not significantly change the formula’s effectiveness.
What the research does not prove
- That lutein supplements prevent AMD in people with healthy eyes.
- That they sharpen normal vision or protect against screen “blue light”.
- That they reduce cataract surgery.
- That products with different doses or extra ingredients match the AREDS2 formula.
Safety
- Lutein and zeaxanthin were well tolerated in AREDS2.
- Eye formulas often contain high-dose zinc; the adult upper limit is 40 mg a day, and excess zinc can cause copper deficiency (NIH ODS).
- Avoid beta-carotene formulas if you smoke or used to smoke.
Limitations of the evidence base
- Main benefit evidence applies to people with intermediate or unilateral late AMD.
- Encouraging lutein findings are secondary analyses.
- Participants were largely well-nourished US adults.
Frequently asked questions
What dose was used in AREDS2?
Lutein 10 mg and zeaxanthin 2 mg daily, added to vitamins C and E, zinc and copper.
Did AREDS2 show lutein works?
The primary analysis was not significant; secondary analyses suggested benefit in some groups.
Should people with healthy eyes take lutein?
AREDS2 studied people at risk of advanced AMD; it does not establish benefit for healthy eyes.
Related on FactoWiki
Lutein ingredient guide · How much lutein and zeaxanthin · Vision & eye category
References
- AREDS2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for AMD: the AREDS2 randomized clinical trial. JAMA. 2013;309(19):2005–2015. PMID 23644932
- AREDS2 Research Group. Secondary analyses of the effects of lutein/zeaxanthin on AMD progression: AREDS2 report no. 3. JAMA Ophthalmol. 2014;132(2):142–149. PMID 24310343
- AREDS2 Research Group. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 report no. 4. JAMA Ophthalmol. 2013;131(7):843–850. PMID 23645227
- National Eye Institute AREDS/AREDS2 FAQ.
- NIH ODS: Zinc fact sheet for health professionals. Link